Pr MD - Apellis Pharmaceuticals Head Board
| APLS Stock | USD 34.14 1.51 4.63% |
Executive
Pr MD is Head Board of Apellis Pharmaceuticals
| Address | 100 Fifth Avenue, Waltham, MA, United States, 02451 |
| Phone | 617 977 5700 |
| Web | https://www.apellis.com |
Apellis Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1623) % which means that it has lost $0.1623 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0656) %, meaning that it created substantial loss on money invested by shareholders. Apellis Pharmaceuticals' management efficiency ratios could be used to measure how well Apellis Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.7 in 2024. Return On Capital Employed is likely to drop to -1 in 2024. At this time, Apellis Pharmaceuticals' Other Current Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 205.1 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 18.2 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Thomas Hare | Madrigal Pharmaceuticals | N/A | |
| Kathryn Haviland | Blueprint Medicines Corp | 48 | |
| Catriona Yale | Akero Therapeutics | 52 | |
| Patrick Lamy | Akero Therapeutics | 51 | |
| Camille MD | Amylyx Pharmaceuticals | 71 | |
| Emil MD | Terns Pharmaceuticals | 44 | |
| Mark Levine | Immunovant | 51 | |
| MD MBA | Immunovant | 56 | |
| Debra Sieminski | Terns Pharmaceuticals | N/A | |
| Clint Wallace | Madrigal Pharmaceuticals | N/A | |
| Shannon Kelley | Madrigal Pharmaceuticals | N/A | |
| Melita Jung | Terns Pharmaceuticals | 47 | |
| Michael CPA | Blueprint Medicines Corp | 52 | |
| PharmD MBA | Madrigal Pharmaceuticals | N/A | |
| Bo Kara | Mereo BioPharma Group | N/A | |
| Soojin Kim | Inozyme Pharma | N/A | |
| Gayle Gironda | Inozyme Pharma | N/A | |
| Jeffrey Jasper | Terns Pharmaceuticals | N/A | |
| Julian Baker | Blueprint Medicines Corp | 57 | |
| Christina MBA | Blueprint Medicines Corp | 48 | |
| Brian JD | Madrigal Pharmaceuticals | 62 | |
Management Performance
| Return On Equity | -1.07 | ||||
| Return On Asset | -0.16 |
Apellis Pharmaceuticals Leadership Team
Elected by the shareholders, the Apellis Pharmaceuticals' board of directors comprises two types of representatives: Apellis Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Apellis. The board's role is to monitor Apellis Pharmaceuticals' management team and ensure that shareholders' interests are well served. Apellis Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Apellis Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Timothy Sullivan, CFO, Treasurer | ||
| Cedric MD, President, CoFounder | ||
| Meredith Kaya, Investor President | ||
| Adam Townsend, Chief Commercial Officer | ||
| James CPA, Corporate VP | ||
| Karen Lewis, Chief Officer | ||
| Nur Nicholson, Chief Officer | ||
| JD Esq, General Counsel | ||
| MBA JD, CoFounder Director | ||
| Pr MD, Head Board | ||
| David Acheson, Senior Commercial | ||
| Lukas MD, Chief Officer | ||
| Mark Delong, Chief Officer | ||
| Federico MD, CoFounder Officer | ||
| Victoria Brown, Senior President | ||
| Pascal Deschatelets, CoFounder Officer | ||
| Caroline MD, Chief Officer | ||
| Jeffrey Eisele, Chief Officer |
Apellis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Apellis Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.07 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (0.35) % | ||||
| Operating Margin | (0.24) % | ||||
| Current Valuation | 4.13 B | ||||
| Shares Outstanding | 124.39 M | ||||
| Shares Owned By Insiders | 13.98 % | ||||
| Shares Owned By Institutions | 98.75 % | ||||
| Number Of Shares Shorted | 23.18 M | ||||
| Price To Earning | (6.94) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.